Synthesis and Preclinical Characterization of [¹⁸F]FPBZA: A Novel PET Probe for Melanoma

Table 1

Biodistribution of ¹⁸FFPBZA in C57BL/6 mice bearing either B16F0 tumor or inflammation and Balb/c nude mice bearing A375 tumor after intravenous injection. Mice were injected with 3.7 MBq of ¹⁸FFPBZA through lateral tail vein. Results were expressed as the percentage of injection dose per gram of organ (%ID/g) (; mean ± SD).

	B16F0 tumor			A375 tumor	Inflammation
	30 min	60 min	120 min	120 min	120 min
Blood	3.78 ± 0.41	2.91 ± 0.18	2.17 ± 0.10	2.48 ± 0.08	2.14 ± 0.22
Heart	3.30 ± 0.42	2.90 ± 0.23	2.26 ± 0.15	2.51 ± 0.21	2.30 ± 0.31
Lung	3.07 ± 0.42	2.37 ± 0.19	1.05 ± 0.32	1.57 ± 0.19	1.19 ± 0.06
Liver	3.43 ± 0.27	2.67 ± 0.25	1.74 ± 0.25	2.04 ± 0.27	1.78 ± 0.21
Stomach	3.17 ± 0.81	2.11 ± 0.58	1.28 ± 0.13	1.48 ± 0.45	1.31 ± 0.07
Si	3.98 ± 1.05	2.45 ± 0.38	1.32 ± 0.19	1.94 ± 0.09	1.48 ± 0.13
Li	4.38 ± 0.58	2.33 ± 0.50	2.41 ± 0.38	2.67 ± 0.19	2.13 ± 0.69
Spleen	3.13 ± 0.52	2.37 ± 0.49	1.42 ± 0.25	1.61 ± 0.58	1.76 ± 0.15
Pancreas	3.09 ± 0.67	2.09 ± 0.31	1.08 ± 0.07	1.07 ± 0.32	1.30 ± 0.26
Muscle	2.83 ± 0.46	1.87 ± 0.21	1.16 ± 0.09	1.26 ± 0.02	1.28 ± 0.07
Bone	2.68 ± 0.38	2.93 ± 0.40	3.21 ± 0.16	3.53 ± 0.10	3.48 ± 0.85
Tumor	10.37 ± 1.13	8.31 ± 1.00	7.81 ± 0.82	3.00 ± 0.71
Kidney	4.92 ± 0.74	3.44 ± 0.44	2.00 ± 0.12	1.97 ± 0.59	2.27 ± 0.79
Eyeball	12.13 ± 0.94	9.74 ± 1.32	7.69 ± 1.56	2.91 ± 0.45	6.55 ± 0.45
Brain	2.24 ± 0.23	2.07 ± 0.15	1.49 ± 0.21	1.89 ± 0.37	1.64 ± 0.16
Inflammation					1.67 ± 0.56
Uptake ratio
Tumor-To-Muscle	3.72 ± 0.53	4.47 ± 0.58	6.60 ± 1.00	2.72 ± 0.05
Tumor-To-Liver	2.90 ± 0.23	3.12 ± 0.33	4.49 ± 0.60	1.70 ± 0.24
Tumor-To-Blood	2.52 ± 0.07	2.86 ± 0.34	3.52 ± 0.51	1.38 ± 0.04
Tumor-To-Brain	4.54 ± 0.20	4.03 ± 0.43	5.19 ± 0.93	1.72 ± 0.03
Tumor-to-lung	3.43 ± 0.56	3.53 ± 0.51	9.01 ± 4.85	2.27 ± 0.32